MIW815 + PDR001

**MIW815 + PDR001** is a combination investigational immunotherapy regimen designed for patients with advanced or metastatic solid tumors or lymphomas. MIW815, also known as ADU-S100, is a synthetic cyclic dinucleotide and a stimulator of interferon genes (STING) pathway agonist, administered via intratumoral injection to activate innate immune responses within the tumor microenvironment. PDR001, also known as spartalizumab, is a fully human monoclonal antibody directed against programmed cell death protein 1 (PD-1), functioning as a checkpoint inhibitor and administered by intravenous infusion. The combination was evaluated primarily for safety, tolerability, pharmacokinetics, preliminary antitumor efficacy, and immune activation. Novartis sponsored and developed the clinical study. The program was terminated before dose expansion due to lack of meaningful antitumor activity in the dose-escalation phase, not for safety reasons[1][2][3][4].

Other names

MIW815 + PDR001ADU-S100 + spartalizumab